Concord Biotech Ltd completes ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility

Concord Biotech Limited has announced the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection took place from June 8 to June 12, 2026, and was concluded successfully.

The successful completion of the ANVISA inspection marks a significant milestone in Concord Biotech's global growth journey. This achievement reinforces our commitment to the highest standards of quality and regulatory excellence while strengthening our global manufacturing and regulatory footprint. It also advances our international expansion strategy by enhancing access to one of the world's largest pharmaceutical markets and broadening the reach of our high-quality APIs across key global geographies.

Shares of Concord Biotech Limited was last trading in BSE at Rs. 1345.30 as compared to the previous close of Rs. 1326.85. The total number of shares traded during the day was 14258 in over 917 trades.

The stock hit an intraday high of Rs. 1349.00 and intraday low of 1299.35. The net turnover during the day was Rs. 18982803.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 ANVISA Inspection Brazil APIFacility Limbasi